FORM |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||
Emerging growth company | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |
(d) Exhibits. | ||||||||||||||
The following exhibit is furnished with this Current Report on Form 8-K: | ||||||||||||||
Exhibit Number | Description of Exhibit | |||||||||||||
99.1 | ||||||||||||||
104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document. |
QUIDELORTHO CORPORATION | ||||||||
By: | /s/ Joseph M. Busky | |||||||
Name: | Joseph M. Busky | |||||||
Its: | Chief Financial Officer |
Three Months Ended | Six Months Ended | ||||||||||||||||||||||
July 3, 2022 (a) | July 4, 2021 | July 3, 2022 (a) | July 4, 2021 | ||||||||||||||||||||
Total revenues | $ | 613.4 | $ | 176.6 | $ | 1,615.7 | $ | 551.9 | |||||||||||||||
Cost of sales, excluding amortization of intangibles | 275.9 | 68.6 | 536.2 | 140.2 | |||||||||||||||||||
Selling, marketing and administrative | 118.4 | 54.2 | 203.2 | 102.9 | |||||||||||||||||||
Research and development | 34.2 | 22.6 | 60.6 | 45.9 | |||||||||||||||||||
Amortization of intangible assets | 21.0 | 6.8 | 28.1 | 13.6 | |||||||||||||||||||
Acquisition and integration costs | 80.2 | 1.1 | 83.2 | 1.8 | |||||||||||||||||||
Other operating expenses | 4.0 | — | 4.0 | — | |||||||||||||||||||
Operating income | 79.7 | 23.3 | 700.4 | 247.5 | |||||||||||||||||||
Interest expense, net | 10.3 | 1.4 | 11.3 | 3.4 | |||||||||||||||||||
Loss on extinguishment of debt | 24.0 | — | 24.0 | — | |||||||||||||||||||
Other expense, net | 2.5 | 0.2 | 1.6 | 0.6 | |||||||||||||||||||
Income before provision for income taxes | 42.9 | 21.7 | 663.5 | 243.5 | |||||||||||||||||||
Provision for income taxes | 23.6 | 2.6 | 164.3 | 46.3 | |||||||||||||||||||
Net income | $ | 19.3 | $ | 19.1 | $ | 499.2 | $ | 197.2 | |||||||||||||||
Basic earnings per share | $ | 0.37 | $ | 0.46 | $ | 10.62 | $ | 4.74 | |||||||||||||||
Diluted earnings per share | $ | 0.36 | $ | 0.45 | $ | 10.47 | $ | 4.64 | |||||||||||||||
Weighted average shares outstanding - basic | 52.2 | 41.7 | 47.0 | 41.6 | |||||||||||||||||||
Weighted average shares outstanding - diluted | 52.9 | 42.4 | 47.7 | 42.5 |
July 3, 2022 (a) | January 2, 2022 | ||||||||||
Cash and cash equivalents | $ | 379.0 | $ | 802.8 | |||||||
Marketable securities | 52.5 | 25.7 | |||||||||
Accounts receivable, net | 379.2 | 378.0 | |||||||||
Inventories | 552.7 | 198.8 | |||||||||
Prepaid expenses and other current assets | 195.7 | 35.0 | |||||||||
Property, plant and equipment, net | 1,110.1 | 349.2 | |||||||||
Marketable securities | 15.2 | 37.9 | |||||||||
Right-of-use assets | 168.9 | 127.6 | |||||||||
Goodwill | 2,589.6 | 337.0 | |||||||||
Intangible assets, net | 3,194.9 | 98.7 | |||||||||
Deferred tax asset | 32.5 | 20.1 | |||||||||
Other assets | 152.1 | 19.6 | |||||||||
Total assets | $ | 8,822.4 | $ | 2,430.4 | |||||||
Accounts payable | $ | 247.3 | $ | 101.5 | |||||||
Accrued payroll and related expenses | 116.9 | 40.4 | |||||||||
Income tax payable | 69.1 | 66.9 | |||||||||
Current portion of borrowings | 207.8 | 0.3 | |||||||||
Other current liabilities | 258.9 | 114.4 | |||||||||
Operating lease liabilities | 168.2 | 128.6 | |||||||||
Long-term borrowings | 2,533.3 | 0.4 | |||||||||
Deferred tax liability | 214.0 | — | |||||||||
Other liabilities | 87.3 | 48.5 | |||||||||
Total liabilities | 3,902.8 | 501.0 | |||||||||
Total stockholders’ equity | 4,919.6 | 1,929.4 | |||||||||
Total liabilities and stockholders’ equity | $ | 8,822.4 | $ | 2,430.4 |
Six Months Ended | |||||||||||
July 3, 2022 (a) | July 4, 2021 | ||||||||||
Cash provided by operating activities | $ | 725.6 | $ | 407.5 | |||||||
Cash used for investing activities | (1,555.1) | (130.3) | |||||||||
Cash provided by (used for) financing activities | 409.7 | (174.0) | |||||||||
Effect of exchange rates changes on cash | (2.4) | 0.1 | |||||||||
(Decrease) increase in cash, cash equivalents and restricted cash | (422.2) | 103.3 | |||||||||
Cash, cash equivalents and restricted cash at beginning of period | 802.8 | 489.9 | |||||||||
Cash, cash equivalents and restricted cash at end of period | $ | 380.6 | $ | 593.2 | |||||||
Reconciliation to amounts within the consolidated balance sheets: | |||||||||||
Cash and cash equivalents | $ | 379.0 | $ | 593.2 | |||||||
Restricted cash in Other assets | 1.6 | — | |||||||||
Cash, cash equivalents and restricted cash | $ | 380.6 | $ | 593.2 |
Three Months Ended | Six Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||
July 3, 2022 | Diluted EPS | July 4, 2021 | Diluted EPS | July 3, 2022 | Diluted EPS | July 4, 2021 | Diluted EPS | ||||||||||||||||||||||||||||||||||||||||
Net income | $ | 19.3 | $ | 0.36 | $ | 19.1 | $ | 0.45 | $ | 499.2 | $ | 10.47 | $ | 197.2 | $ | 4.64 | |||||||||||||||||||||||||||||||
Adjustments: | |||||||||||||||||||||||||||||||||||||||||||||||
Amortization of intangibles | 21.0 | 6.8 | 28.1 | 13.6 | |||||||||||||||||||||||||||||||||||||||||||
Acquisition and integration costs | 80.2 | 1.1 | 83.2 | 1.8 | |||||||||||||||||||||||||||||||||||||||||||
Loss on extinguishment of debt | 24.0 | — | 24.0 | — | |||||||||||||||||||||||||||||||||||||||||||
Unwind inventory fair value adjustment | 11.2 | — | 11.2 | — | |||||||||||||||||||||||||||||||||||||||||||
Noncash interest expense for deferred consideration | 0.8 | 1.1 | 1.7 | 2.6 | |||||||||||||||||||||||||||||||||||||||||||
Amortization of deferred cloud computing implementation costs | 1.3 | 1.2 | 2.3 | 1.9 | |||||||||||||||||||||||||||||||||||||||||||
Derivative mark-to-market gain | (1.0) | — | (1.0) | — | |||||||||||||||||||||||||||||||||||||||||||
Loss on investments | 0.8 | — | 0.8 | — | |||||||||||||||||||||||||||||||||||||||||||
Employee compensation charges and other costs | 0.5 | — | 0.5 | — | |||||||||||||||||||||||||||||||||||||||||||
EU medical device regulation transition costs | 0.4 | — | 0.4 | — | |||||||||||||||||||||||||||||||||||||||||||
Change in fair value of acquisition contingencies | 0.1 | 0.1 | 0.1 | 0.1 | |||||||||||||||||||||||||||||||||||||||||||
Income tax impact of adjustments | (34.9) | (3.6) | (37.5) | (7.1) | |||||||||||||||||||||||||||||||||||||||||||
Adjusted net income | $ | 123.7 | $ | 2.34 | $ | 25.8 | $ | 0.61 | $ | 613.0 | $ | 12.85 | $ | 210.1 | $ | 4.94 | |||||||||||||||||||||||||||||||
Ortho pre-combination adjusted net income | 20.2 | 39.1 | 77.2 | 94.3 | |||||||||||||||||||||||||||||||||||||||||||
Supplemental combined adjusted net income | $ | 143.9 | $ | 2.12 | $ | 64.9 | $ | 0.95 | $ | 690.2 | $ | 10.15 | $ | 304.4 | $ | 4.48 |
Three Months Ended | Six Months Ended | ||||||||||||||||||||||
July 3, 2022 (a) | July 4, 2021 | July 3, 2022 (a) | July 4, 2021 | ||||||||||||||||||||
Net income | $ | 19.3 | $ | 19.1 | $ | 499.2 | $ | 197.2 | |||||||||||||||
Depreciation and amortization | 47.5 | 12.3 | 62.8 | 24.6 | |||||||||||||||||||
Interest expense, net | 10.3 | 1.4 | 11.3 | 3.4 | |||||||||||||||||||
Provision for income taxes | 23.6 | 2.6 | 164.3 | 46.3 | |||||||||||||||||||
Loss on extinguishment of debt | 24.0 | — | 24.0 | — | |||||||||||||||||||
Employee compensation charges and other costs | 0.5 | — | 0.5 | — | |||||||||||||||||||
Acquisition and integration costs | 80.2 | 1.1 | 83.2 | 1.8 | |||||||||||||||||||
Unwind inventory fair value adjustment | 11.2 | — | 11.2 | — | |||||||||||||||||||
Derivative mark-to-market gain | (1.0) | — | (1.0) | — | |||||||||||||||||||
EU medical device regulation transition costs | 0.4 | — | 0.4 | — | |||||||||||||||||||
Loss on investments | 0.8 | — | 0.8 | — | |||||||||||||||||||
Amortization of deferred cloud computing implementation costs | 1.3 | 1.2 | 2.3 | 1.9 | |||||||||||||||||||
Change in fair value of acquisition contingencies | 0.1 | 0.1 | 0.1 | 0.1 | |||||||||||||||||||
Adjusted EBITDA | $ | 218.2 | $ | 37.8 | $ | 859.1 | $ | 275.3 | |||||||||||||||
Ortho pre-combination Adjusted EBITDA | 72.6 | 128.1 | 212.5 | 280.6 | |||||||||||||||||||
Supplemental combined Adjusted EBITDA | $ | 290.8 | $ | 165.9 | $ | 1,071.6 | $ | 555.9 | |||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||||||||||
July 3, 2022 | July 4, 2021 | % Change | Currency Impact | Constant Currency (a) | Less: COVID-19 revenue impact | Constant Currency, ex COVID-19 revenue | |||||||||||||||||||||||||||||||||||
Labs | $ | 342.0 | $ | 340.5 | 0.4 | % | (2.7) | % | 3.1 | % | 2.9 | % | 6.0 | % | |||||||||||||||||||||||||||
Transfusion Medicine | 168.8 | 162.4 | 3.9 | % | (5.0) | % | 8.9 | % | — | % | 8.9 | % | |||||||||||||||||||||||||||||
Point-of-Care | 367.0 | 131.7 | 178.7 | % | (1.8) | % | 180.5 | % | (161.1) | % | 19.4 | % | |||||||||||||||||||||||||||||
Molecular Diagnostics | 20.7 | 34.5 | (40.0) | % | (0.4) | % | (39.6) | % | 84.4 | % | 44.8 | % | |||||||||||||||||||||||||||||
Total supplemental combined revenues | $ | 898.5 | $ | 669.1 | 34.3 | % | (3.2) | % | 37.5 | % | (28.5) | % | 9.0 | % |
Three Months Ended | |||||||||||||||||||||||||||||||||||||||||
July 3, 2022 | July 4, 2021 | % Change | Currency Impact | Constant Currency (a) | Less: COVID-19 revenue impact | Constant Currency, ex COVID-19 revenue | |||||||||||||||||||||||||||||||||||
North America | $ | 595.7 | $ | 375.3 | 58.7 | % | (0.2) | % | 58.9 | % | (43.2) | % | 15.7 | % | |||||||||||||||||||||||||||
EMEA | 82.9 | 85.7 | (3.3) | % | (9.0) | % | 5.7 | % | 2.0 | % | 7.7 | % | |||||||||||||||||||||||||||||
China | 96.1 | 78.7 | 22.1 | % | (3.2) | % | 25.3 | % | (34.9) | % | (9.6) | % | |||||||||||||||||||||||||||||
Other | 123.8 | 129.4 | (4.3) | % | (6.5) | % | 2.2 | % | 2.5 | % | 4.7 | % | |||||||||||||||||||||||||||||
Total supplemental combined revenues | $ | 898.5 | $ | 669.1 | 34.3 | % | (3.2) | % | 37.5 | % | (28.5) | % | 9.0 | % |
Six Months Ended | |||||||||||||||||||||||||||||||||||||||||
July 3, 2022 | July 4, 2021 | % Change | Currency Impact | Constant Currency (a) | Less: COVID-19 revenue impact | Constant Currency, ex COVID-19 revenue | |||||||||||||||||||||||||||||||||||
Labs | $ | 681.7 | $ | 696.7 | (2.2) | % | (1.7) | % | (0.5) | % | 3.9 | % | 3.4 | % | |||||||||||||||||||||||||||
Transfusion Medicine | 342.5 | 323.8 | 5.8 | % | (3.9) | % | 9.7 | % | — | % | 9.7 | % | |||||||||||||||||||||||||||||
Point-of-Care | 1,310.0 | 436.0 | 200.5 | % | (1.2) | % | 201.7 | % | (158.6) | % | 43.1 | % | |||||||||||||||||||||||||||||
Molecular Diagnostics | 66.7 | 94.7 | (29.6) | % | (0.1) | % | (29.5) | % | 60.0 | % | 30.5 | % | |||||||||||||||||||||||||||||
Total supplemental combined revenues | $ | 2,400.9 | $ | 1,551.2 | 54.8 | % | (2.4) | % | 57.2 | % | (45.9) | % | 11.3 | % |
Six Months Ended | |||||||||||||||||||||||||||||||||||||||||
July 3, 2022 | July 4, 2021 | % Change | Currency Impact | Constant Currency (a) | Less: COVID-19 revenue impact | Constant Currency, ex COVID-19 revenue | |||||||||||||||||||||||||||||||||||
North America | $ | 1,833.5 | $ | 972.3 | 88.6 | % | (0.1) | % | 88.7 | % | (69.6) | % | 19.1 | % | |||||||||||||||||||||||||||
EMEA | 166.9 | 175.3 | (4.8) | % | (7.4) | % | 2.6 | % | 3.8 | % | 6.4 | % | |||||||||||||||||||||||||||||
China | 159.4 | 148.2 | 7.6 | % | (1.0) | % | 8.6 | % | (18.6) | % | (10.0) | % | |||||||||||||||||||||||||||||
Other | 241.1 | 255.4 | (5.6) | % | (4.8) | % | (0.8) | % | 6.8 | % | 6.0 | % | |||||||||||||||||||||||||||||
Total supplemental combined revenues | $ | 2,400.9 | $ | 1,551.2 | 54.8 | % | (2.4) | % | 57.2 | % | (45.9) | % | 11.3 | % |
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end
Document and Entity Information Document |
Aug. 04, 2022 |
---|---|
Entity Information [Line Items] | |
Document Type | 8-K |
Document Period End Date | Aug. 04, 2022 |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-41409 |
Entity Tax Identification Number | 87-4496285 |
Entity Address, Address Line One | 9975 Summers Ridge Road |
Entity Address, City or Town | San Diego |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92121 |
City Area Code | 858 |
Local Phone Number | 552-1100 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.001 Par Value |
Trading Symbol | QDEL |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001906324 |
Amendment Flag | false |
Entity Registrant Name | QUIDELORTHO CORP |
X/^^3-&4KKB%-@'2RIW"AYZ]C
MZ/.GZ?S3$QD]32=U=.[1KM/NX+]0VS2:)&P)FM[%%7BWVFV*=P,CLV(CNI &
MMK7%Z9I1,#'[ -Q?2FD. [NW+?\U,?@?4$L#!!0 ( %J$!%6?H!OPL0(
M .(, - >&PO -8?20$3;8T.P6BP^0"X99K>]9!:G
-(.CF5+JBJ=U@_/V@,X
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M=E2" ;+/V3BW1N,>& /<$7&2T$\P1W_F!SSJ [^_GR*F^6'K,
MX3D0"\81"<")8QJS 64,
L* =A@S>^!N+#91!V8E'3E[NRHZET&^EGK7>X#F7\ 5 =C\
M+])ZI8C@[R#B./72S62S,YD-=3V"!99XAT)-:['(CI-I,3L.9(0!;>(U%PP8
M.1+H"@!8E,ZSJ;:5.-??P":J[=NV6=I3^_^R(5OO+AM\ G;SCYO0PU2F\@
MC=Y9:/K(E4"I+!RHKSR*1/F^ UT'W_KANU;_EGV$QS%(D(WLX>>S =/YTO4
MGX(1?A+N\OUH7*0WKT9B'L40E*A ,NUQ($>CHW,2:QI#R07)$?G#";2,%:*!
M3I=_/JEW*P>G+1&?80P 7QHJS,$O/AL*7(,RP;MSLQ OR^!B
:EP&+[*>FU,K=:YS2W
MR!#>P1EB3#D98W3S-P\CUIPF%-8])V=JZCS^ZH=N?Z3
M$-AT%".M*BUI37@P%J%,3_K11 1P.8PNP\'4*3E93L844P'$')*:2V;,V:6F
MID[FG?47>);.O(K'\2(Q#I+EL_!B636SK%^KDT_JQ!FC3B>.U(DQ_1:)3#DY
M8^0NL2+_';DZ/@@O\H,G-N).P!ZX&XM,SZ&+<"P-HVB#5+*1:VXC
M$W-(;*K'F;.+34U=R[?PV(/358,.M/V^UBT9-R\H%5H# .7;9$38(>PL*9^R'>!" *H2@*Z[
MN;:Z$G@(/!G/:U"T.T;M %33OAGO/KR[NX@V&4:WFWOW#G5C. UK>IW<_C*Q
MYC360UOKT[9XPL%U+\\N$,)!77%@Y@Z%$1;JBH5S'9%#6"@?I;JY3VFK-A9J
MFE2_GSC>6C(]3\RC,H U.H.B!PM6-!-7'=:T^V?::DJLV<.:7M%,:$75/&%A
MATMH:#IM 28<%*Z.("S4#@O7!K75)R!((.B7LSK4-#7X>S01P47D!LVVD3O/
M30FHT["FTSE3:(E8LT_'=ZB'/N&